Natalia Manilo
Glostrup, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
Journal: RMD open
Published: October 13, 2022
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Journal: RMD open
Published: July 05, 2022
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Journal: Annals of the rheumatic diseases
Published: January 19, 2021
Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
Journal: Rheumatology (Oxford, England)
Published: December 21, 2020
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Journal: Annals of the rheumatic diseases
Published: November 25, 2019
Association between MRI findings and patient-reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse.
Journal: International journal of rheumatic diseases
Published: July 30, 2019
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Journal: Annals of the rheumatic diseases
Published: January 02, 2019
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Journal: Annals of the rheumatic diseases
Published: December 04, 2018
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Journal: Annals of the rheumatic diseases
Published: March 26, 2018
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Journal: Rheumatology (Oxford, England)
Published: January 18, 2018
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Journal: Clinical epidemiology
Published: December 15, 2017
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Journal: Annals of the rheumatic diseases
Published: October 28, 2016
Last Updated: 09/26/2026